Mirum Pharmaceuticals Inc. - notizie pubblicate 214 - letture 2.277
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Submission of Matters to a Vote of Security Holders Form 8 K
Item 5.07 submission of matters to a vote of security holders. on june 5, 2024, the company held its 2024 annual meeting of stockholders (the "annual meeting"). as of apr ...
MIRUM PHARMACEUTICALS INC.
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
- data showcases sustained clinical benefit following seven years of livmarli treatment in patients with alagille syndrome - long-term extension data from livmarli pfic studies hig ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm), a biopharmaceutical company focused on the identification, acquisition, development and commercia ...
MIRUM PHARMACEUTICALS INC.
Material Event - Form 8-K
Item 8.01 other events. on may 31, 2024, mirum pharmaceuticals, inc. (the "company") announced that the european committee for medicinal products for human use ("chm ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
Positive opinion from chmp based on phase 3 march study with highly statistically significant (p<0.0001) reduction in pruritus severity between livmarli vs. placebo across all p ...
MIRUM PHARMACEUTICALS INC.
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
Long-term data from mirum's livmarli studies in algs and pfic to be presented at easl congress may 29, 2024 - data showcases sustained clinical benefit following 7 years of livmarl ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- seven abstracts highlighting algs and pfic data, including three oral presentations - long-term extension data from phase 3 march-on pfic study presented at plenary session and s ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti